A Judge Let Eli Lilly's Ads Keep Running. Novo Nordisk's Own Numbers Say Ads Were Never the Problem.

The judge framed the case as a question of remedy, not of truth: he denied the injunction on irreparable harm and left the merits for trial. Novo Nordisk \"failed to show\" that the ads threatened its sales, undermined its goodwill or damaged its clinical reputation, and in a 25-page decision the judge reasoned that money damages can compensate for any nontrivial harm. He also put the commercials' commercial impact in context: between April and July, while the campaign was running, the ads had at most a negligible market impact and Novo's prescriptions stayed stable. He did not decide whether Lilly's comparisons are true.

The judge examined the only evidence the record had — what happened to Novo's prescriptions while the commercials aired — and found the answer was negligible. Novo Nordisk's own filings tell the same story from the other side. US Wegovy injectable sales fell 17% at constant exchange rates in H1 2026 even as the campaign ran, yet total US obesity care sales still grew 4% in Q2 because the portfolio added volume and the new Wegovy pill started taking share from the injectable, grew 4% on volume even as realized prices fell.

Here is the causal chain that matters for the next two years. A comparative campaign is a price-and-format story: it pushes patients toward whichever brand claims the better number, and in 2026 the better number belongs to a daily pill. Oral semaglutide was already 35% of all Wegovy prescriptions in the week ended Aug 28, 2026, while Lilly's Foundayo was still running at roughly 20,000 scripts in its ninth week. A daily pill generates about seven times as many dosing events per patient-year as a weekly injection, so the format shift inflates physical drug volume whether or not a single commercial is ever pulled.

Lilly is spending more on promotion than ever and less of it per dollar of revenue: marketing, selling and administrative costs rose 25% to $3.43B in Q2 2026, yet slipped from 17.7% to 14.9% of revenue because revenue grew 48%. Novo cut its sales and distribution costs 16.5% to DKK 27.07B in H1 2026. A company that cuts commercial spending 16.5% while its US injectable line shrinks 17% has stopped believing its advertising works — which is exactly the belief the judge tested and found unsupported.

The mechanism is brand disintermediation. Eli Lilly now sells the two most wanted GLP-1s in the country without a middleman: Foundayo at $149 a month for self-pay patients and $25 a month for eligible commercially insured patients, and Zepbound self-pay from $299 a month at the starting dose to $449 a month for 7.5 mg and above, against a list price of up to $1,086.37 a fill. Every ad that moves a patient toward a brand drags that patient out of the cash-pay channel's economics and into the manufacturer's own. Hims & Hers shows the result: revenue up 38% and gross margin down 12 points to 64%.

The legal outcome barely touches this layer, which is why it holds the cleanest exposure. Component, pen and peptide suppliers are paid on doses shipped and patients treated, not on whose billboard is up. WuXi AppTec raised 2026 revenue guidance to RMB 58.5–60.5B and capex to RMB 7.5–8.5B; West Pharmaceutical Services grew net sales 13.8% in Q2 on GLP-1 elastomers; Becton Dickinson is winning pen platforms for semaglutide launches. None of those orders depends on who wins the advertising case.

Three facts, one inference. Fact one: on Oct 26, 2026 a federal judge let Eli Lilly's comparative commercials keep running and found they had at most a negligible effect on Novo Nordisk's prescriptions. Fact two: in the quarters behind that ruling, Eli Lilly was growing US volume 37% on a 3% price cut while Novo Nordisk guided 2026 adjusted sales to between 0% and -6% at constant exchange rates. Fact three: downstream cash-pay gross margin fell to 64% while the suppliers of doses and components grew revenue 13.8% to 38.9%. The inference: share in obesity is being bought and sold with price and format, and the media war is the loudest part of a fight being settled somewhere else entirely.